Startseite › Lungenkrebs › Oregon › Portland
Klinische Studien zu Lungenkrebs in Portland, OR
26 Studien zu Lungenkrebs suchen Teilnehmer an Standorten in und um Portland (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- Oregon Health & Science University (OHSU), Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi entfernt
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Teilnehmer gesuchtPhase 1/2
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- PHN-012-001 Site, Portland
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Teilnehmer gesuchtPhase 3
- Oregon Health and Science University ( Site 0052), Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Northwest Cancer Specialists, P.C., Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Teilnehmer gesuchtPhase 2/3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Teilnehmer gesuchtPhase 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Providence Portland Medical Center, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Oregon Health and Science University, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Teilnehmer gesuchtPhase 1/2
- Providence Portland Medical Center, Portland
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Teilnehmer gesuchtPhase 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Teilnehmer gesuchtPhase 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- und 2 weitere
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- und 2 weitere
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Teilnehmer gesuchtPhase 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- und 1 weitere
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Teilnehmer gesuchtBeobachtungsstudie
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi entfernt
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Portland
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Teilnehmer gesuchtBeobachtungsstudie
- Oregon Health & Science University, Portland
Lungenkrebs-Studien in anderen Städten
- Houston, TX78 Studien
- Boston, MA62 Studien
- New York City, NY60 Studien
- Los Angeles, CA45 Studien
- Washington, DC41 Studien
- Arlington, VA41 Studien
- Chicago, IL41 Studien
- Nashville, TN40 Studien
- Baltimore, MD40 Studien
- St. Louis, MO39 Studien
- Columbus, OH37 Studien
- Philadelphia, PA36 Studien
Weitere Studien in Portland
- Nichtkleinzelliges Lungenkarzinom46 Studien
- Krebs (alle Arten)34 Studien
- Prostatakrebs33 Studien
- Brustkrebs33 Studien
- Metastasierender Krebs29 Studien
- Kolorektales Karzinom28 Studien
- Eierstockkrebs27 Studien
- Akute myeloische Leukämie25 Studien
- Endometriumkarzinom24 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich19 Studien
- Bauchspeicheldrüsenkrebs19 Studien
- Herzinsuffizienz17 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.